Literature DB >> 19667293

Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure.

Signe Fransen1, Marina Karmochkine, Wei Huang, Laurence Weiss, Christos J Petropoulos, Charlotte Charpentier.   

Abstract

We characterized the raltegravir (RAL) susceptibility and the integrase (IN)-mediated replication capacity (RC) of RAL-resistant human immunodeficiency virus type 1 from two patients experiencing virologic failure during continuous RAL salvage therapy. The following two distinct outcomes were observed: (i) the selective outgrowth of virus with high-level RAL resistance and high IN-mediated RC leading to significant viral load rebound and (ii) the selection of virus with a slight reduction in RAL susceptibility and low IN-mediated RC resulting in sustained low-level viremia.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19667293      PMCID： PMC2764161          DOI： 10.1128/AAC.00651-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo.

Authors:  Signe Fransen; Soumi Gupta; Arne Frantzell; Christos J Petropoulos; Wei Huang
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

2.  A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.

Authors:  C J Petropoulos; N T Parkin; K L Limoli; Y S Lie; T Wrin; W Huang; H Tian; D Smith; G A Winslow; D J Capon; J M Whitcomb
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

3.  Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.

Authors:  Isabelle Malet; Olivier Delelis; Cathia Soulie; Marc Wirden; Luba Tchertanov; Philippe Mottaz; Gilles Peytavin; Christine Katlama; Jean-François Mouscadet; Vincent Calvez; Anne-Genevieve Marcelin
Journal:  J Antimicrob Chemother       Date:  2009-02-16       Impact factor: 5.790

4.  Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.

Authors:  C Charpentier; M Karmochkine; D Laureillard; P Tisserand; L Bélec; L Weiss; A Si-Mohamed; C Piketty
Journal:  HIV Med       Date:  2008-07-21       Impact factor: 3.180

5.  Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

Authors:  David A Cooper; Roy T Steigbigel; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey L Lennox; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Hedy Teppler; Bach-Yen Nguyen
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245
  5 in total
  27 in total

Review 1.  Drug resistance in HIV-1.

Authors:  Daniel R Kuritzkes
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

2.  Switching between raltegravir resistance pathways analyzed by deep sequencing.

Authors:  Rithun Mukherjee; Shane T Jensen; Frances Male; Kyle Bittinger; Richard L Hodinka; Michael D Miller; Frederic D Bushman
Journal:  AIDS       Date:  2011-10-23       Impact factor: 4.177

Review 3.  Authentic HIV-1 integrase inhibitors.

Authors:  Chenzhong Liao; Christophe Marchand; Terrence R Burke; Yves Pommier; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

4.  Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.

Authors:  Charlotte Charpentier; Bénédicte Roquebert; Olivier Delelis; Lucile Larrouy; Sophie Matheron; Roland Tubiana; Marina Karmochkine; Xavier Duval; Geneviève Chêne; Alexandre Storto; Gilles Collin; Antoine Bénard; Florence Damond; Jean-François Mouscadet; Françoise Brun-Vézinet; Diane Descamps
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

5.  Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice.

Authors:  Alonso Heredia; Said Hassounah; Sandra Medina-Moreno; Juan C Zapata; Nhut M Le; Yingshan Han; James S Foulke; Charles Davis; Joseph Bryant; Robert R Redfield; Mark A Wainberg
Journal:  J Antimicrob Chemother       Date:  2017-09-01       Impact factor: 5.790

6.  Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.

Authors:  Mathieu Métifiot; Kasthuraiah Maddali; Alena Naumova; Xuemin Zhang; Christophe Marchand; Yves Pommier
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

7.  The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes.

Authors:  Saleta Sierra; Nadine Lübke; Hauke Walter; Eugen Schülter; Stefan Reuter; Gerd Fätkenheuer; Markus Bickel; Hugo da Silva; Rolf Kaiser; Stefan Esser
Journal:  Med Microbiol Immunol       Date:  2011-04-08       Impact factor: 3.402

8.  HIV Drug Resistance and the Advent of Integrase Inhibitors.

Authors:  Peter K Quashie; Thibault Mesplède; Mark A Wainberg
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

9.  Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.

Authors:  Krishan K Pandey
Journal:  Clin Med Rev Ther       Date:  2011-12-20

Review 10.  HIV resistance to raltegravir.

Authors:  Francois Clavel
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.